Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SCTV01C Booster in mRNA-Vaccinated Adults
NCT05043311Phase 2Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sctv01c in coronavirus disease 2019 (COVID-19), sponsored by Sinocelltech Group Limited. Status: unknown.
02
Drugs
sctv01c
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05043311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043311.